In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Erytech Pharma SA (NASDAQ: ERYP). The company’s shares opened today at $17.87.
According to TipRanks.com, Peaker is a 5-star analyst with an average return of 17.2% and a 52.1% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Mersana Therapeutics Inc, and CytomX Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Erytech Pharma SA.
See today’s analyst top recommended stocks >>
The company has a one-year high of $32.33 and a one-year low of $12.75. Currently, Erytech Pharma SA has an average volume of 644.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. It engages in developing and producing therapeutic products for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.
